Prompt cancer diagnosis may align UK survival with European averages. We examined the impact of route to diagnosis on survival for multiple myeloma patients diagnosed 2012–2013 using data from our population‐based patient cohort that links to national death notifications and collects details on treatment and response (n = 441). Emergency presentation was associated with advanced disease and poorer outcomes, and was the commonest route to diagnosis (28·1%) followed by General Practitioner urgent (19·0%) and two‐week wait (17·2%) referrals. CRAB (elevated Calcium, Renal failure, Anaemia, Bone lesions) distribution varied by route (P < 0·001), with patients with emergency presentations most likely to have ≥2 features and significantly worse su...
Registry data are important for monitoring the impact of new therapies on treatment algorithms and o...
Multiple myeloma is the second most common haematological malignancy in high-income countries, and t...
Multiple Myeloma (MM) is a hematologic malignancy that accounts for approximately 1% of all adult ca...
Prompt cancer diagnosis may align UK survival with European averages. We examined the impact of rout...
Prompt cancer diagnosis may align UK survival with European averages. We examined the impact of rout...
This is the author accepted manuscript. The final version is available from Royal College of General...
BACKGROUND: Multiple myeloma is an uncommon cancer with a poor prognosis. Its incidence is expected ...
Advances in novel agents and treatment combinations have improved prognosis and increased disease-fr...
© 2018 Howell et al. This is an open access article distributed under the terms of the Creative Comm...
Multiple myeloma is associated with significant early morbidity and mortality, with considerable end...
OBJECTIVES: This study aimed to provide real-world data on the characteristics and treatment of pati...
Introduction Clinical trials have shown improved response rates, progression-free survival and overa...
There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The...
With increasing number of therapies available for the treatment of multiple myeloma, it is timely to...
BACKGROUND: Pathways to myeloma diagnosis can be prolonged, and are often preceded by multiple GP co...
Registry data are important for monitoring the impact of new therapies on treatment algorithms and o...
Multiple myeloma is the second most common haematological malignancy in high-income countries, and t...
Multiple Myeloma (MM) is a hematologic malignancy that accounts for approximately 1% of all adult ca...
Prompt cancer diagnosis may align UK survival with European averages. We examined the impact of rout...
Prompt cancer diagnosis may align UK survival with European averages. We examined the impact of rout...
This is the author accepted manuscript. The final version is available from Royal College of General...
BACKGROUND: Multiple myeloma is an uncommon cancer with a poor prognosis. Its incidence is expected ...
Advances in novel agents and treatment combinations have improved prognosis and increased disease-fr...
© 2018 Howell et al. This is an open access article distributed under the terms of the Creative Comm...
Multiple myeloma is associated with significant early morbidity and mortality, with considerable end...
OBJECTIVES: This study aimed to provide real-world data on the characteristics and treatment of pati...
Introduction Clinical trials have shown improved response rates, progression-free survival and overa...
There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The...
With increasing number of therapies available for the treatment of multiple myeloma, it is timely to...
BACKGROUND: Pathways to myeloma diagnosis can be prolonged, and are often preceded by multiple GP co...
Registry data are important for monitoring the impact of new therapies on treatment algorithms and o...
Multiple myeloma is the second most common haematological malignancy in high-income countries, and t...
Multiple Myeloma (MM) is a hematologic malignancy that accounts for approximately 1% of all adult ca...